Status:
UNKNOWN
Anticoagulation-free VV ECMO for Acute Respiratory Failure
Lead Sponsor:
Damian Ratano
Collaborating Sponsors:
PSI Foundation, Toronto, Ontario
Conditions:
Extracorporeal Membrane Oxygenation Complication
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
Currently international experts recommend therapeutic anticoagulation for veno-venous extracorporeal membrane oxygenation (VV-ECMO). Reports and case series suggest that the absence of therapeutic ant...
Detailed Description
Although anticoagulation targets and monitoring strategies vary around the world, the current practice is still to anticoagulate patients on ECMO, mostly with UFH. However, the use of heparin coated c...
Eligibility Criteria
Inclusion
- Adult patient with ARDS on VV-ECMO
Exclusion
- Contraindication to anticoagulation with UFH (known heparin-induced thrombocytopenia, active hemorrhage, any surgery precluding the use of anticoagulation),
- Indication for therapeutic anticoagulation (pulmonary embolism or deep vein thrombosis, chronic anticoagulation therapy before ECMO insertion)
- Low-flow (\<2 liters/min) VV-ECMO (ECCO2R)
Key Trial Info
Start Date :
September 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2024
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04273607
Start Date
September 1 2022
End Date
June 30 2024
Last Update
August 24 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Toronto General Hospital
Toronto, Ontario, Canada, M5G 2N2